The Pharma Data

MARCH 1, 2022

This acquisition gives AbbVie access to Syndesi’s portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. ” The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. .

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

NOVEMBER 22, 2020

Omecamtiv mecarbil is an investigational cardiac myosin activator, developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF), and was recently studied in GALACTIC-HF, a positive Phase 3 cardiovascular outcomes clinical trial. After a median duration of follow-up of 21.8

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52

The Pharma Data

MARCH 4, 2021

Our goal is to one day bring new treatment options that provide greater seizure control, tolerability and function to DS and LGS patients around the world.”. Advancing New Treatment Options for DS and LGS Patients. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. selective GABA A receptor agonist.

Treatment 52

Treatment Pharmaceutical Companies Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 18, 2020

Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. Title: OBI-833 was safe and immunogenic, without treatment-related SAEs, in a Phase 1 dose-escalation trial. Session Title: E-poster Display session – Thoracic tumours, metastatic. Session Date and Time: Friday, November 20, 2020. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

JANUARY 13, 2021

The patent application is titled “Anti-CD154 Antibodies and Uses Thereof” and published under International Publication No. International Immunol. (11):1583 include: infliximab (Remicade®), adalimumab (Humira®), certolizumab pegol (Cimzia®), and golimumab (Simponi®) for the treatment of certain autoimmune conditions. Structure.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

MAY 6, 2021

The IOC and International Paralympics Committee (IPC) have made it clear that vaccination is not mandatory in order for athletes to participate in the Olympic and Paralympic Games, and that any vaccination program must be conducted in full respect of national vaccination priorities.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Discovery World

MAY 11, 2023

The Phase II trial is part of a new agreement between US-based pharmaceutical company Algok Bio and BTG International, which partnered with the ICR earlier in the drug’s development. Algok Bio’s exclusive license agreement with BTG grants the former the rights to develop and commercialise idetrexed worldwide.

Trials 130

Trials Small Molecule Drugs Pharmaceutical Companies 130

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. 5% have US Food and Drug Administration -approved treatments. Click here for available international numbers.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

NOVEMBER 4, 2020

CTP-543: An Investigational Treatment for Moderate to Severe Alopecia Areata. The presentation highlighted that in the open label extension study, treatment with CTP-543 shows continued maintenance of hair regrowth relative to the hair growth shown in the Company’s previously conducted Phase 2 trials in patients with alopecia areata.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Small Molecule 52

The Pharma Data

OCTOBER 26, 2020

billion related to certain license and collaboration agreements, and certain other items. Non-GAAP EPS of $1.74 for the third quarter of 2020 excludes acquisition- and divestiture-related costs, restructuring costs, pretax charges of $1.1 Year-to-date results can be found in the attached tables. COVID-19 Research Highlights.

Vaccine 40

Vaccine Trials Licensing Licensing 40

The Pharma Data

SEPTEMBER 9, 2020

Today’s decision is a further illustration of how collaboration and solidarity can help address a global health crisis as an international community,” said Ugur Sahin, M.D., Our aim is to develop a safe and effective vaccine to contribute to bringing this pandemic to an end in Europe and across the world. CEO and Co-founder of BioNTech.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

Agency IQ

NOVEMBER 3, 2023

One non-profit organization, the International Society Association for Probiotics and Prebiotics (ISAPP) , which is dedicated to promoting research in this area, has published consensus statements that have helped to define some of these terms and their associated substances.

Therapies 40

Therapies Science FDA Production 40

Drug Discovery World

AUGUST 5, 2022

One of these may be lack of internal resources to carry out particular tasks. In return, they will become as invested professionally as any internal team member. Companies can grow organically, recruiting and building internal teams which is both distracting and time consuming. A strategic partnership.

Drug Development 130

Drug Development Drugs Pharma Companies International 130

The Pharma Data

AUGUST 3, 2021

The FDA has broadened the Emergency Use Authorization (EUA) for baricitinib to allow for treatment with or without remdesivir. The European Commission granted marketing authorization for Jardiance ® as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure).

Production 52

Production Marketing Research Government 52

The Pharma Data

AUGUST 3, 2021

“As we look to the balance of the year, we are excited to be launching LUMAKRAS , a first-in-class lung cancer treatment, and advancing a robust pipeline of potential new medicines to meet the demands of patients around the world.” Bradway, chairman and chief executive officer. With Parsabiv’s inclusion in the U.S.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

(LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Cambridge, UK.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 8, 2020

We have done this by both internal talent development as well as by external hires. All Almirall’s production sites continue to operate at full capacity in order to be able to ensure the supply of medicines to all patients requiring treatment. Almirall maintains its commitment to patients in this unique situation.

Licensing 52

Licensing Licensing Marketing Production 52

The Pharma Data

DECEMBER 15, 2020

Treatment induced sustainable clinical responses and reduced systemic inflammation. Daratumumab already is approved for the treatment of multiple myeloma. The company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

FEBRUARY 4, 2021

Net Revenues of $4.305 Billion and International Profit Sharing of $1.009 Billion; Global Venclexta Net Revenues Were $1.337 Billion. net revenues of $1.165 billion and international profit sharing of $259 million. . – Full-Year Global Net Revenues from the Immunology Portfolio Were $22.153 Billion, an Increase of 13.2

Production 52

Production International Clinical Trials Small Molecule 52

The Pharma Data

SEPTEMBER 15, 2020

The results demonstrated that Penta immune responses were robust and noninferior to licensed meningococcal vaccines (MenB and MenACWY) in individuals 10-25 years of age, regardless of prior MenACWY exposure. The prophylactic steroid treatment was also changed from 1 mg/kg to an intermediate dose of 2mg/kg. Internal Medicine.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

APRIL 27, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June 2020 and is listed on the NRDL (National Reimbursement Drug List) as of March 2021. reflecting lower treatment compliance during the COVID-19 pandemic. First-quarter Fabrazyme ® sales increased 4.7% In the U.S. sales decreased 2.9%

Vaccine 52

Vaccine Production FDA FDA Approval 52

The Pharma Data

DECEMBER 27, 2020

The NRDL’s inclusion of tislelizumab, BRUKINSA, and XGEVA will help expand access to these high-quality oncology treatments across China and alleviate the financial burden for many cancer patients and their families. “We

Production 52

Production Therapies Treatment Drugs 52

The Pharma Data

JUNE 24, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer?BioNTech anaphylaxis) to any component of the Pfizer?BioNTech

Government 52

Government Vaccine Clinical Trials Licensing 52